|
Patent landscape, scope, and claims: |
SUMMARY
Patent 6,121,291, issued to Eli Lilly and Company on September 19, 2000, pertains to methods of preventing and treating osteoporosis using bisphosphonate compounds, particularly alendronate. This detailed analysis examines the scope and claims of the patent, reviews its patent landscape, including related patents, and provides insights pertinent to stakeholders involved in osteoporosis therapeutics and bisphosphonate patent portfolios.
What Is the Scope of Patent 6,121,291?
Patent Scope Overview:
Patent 6,121,291 claims methods of administering bisphosphonate compounds, especially alendronate, to prevent and treat osteoporosis and other bone resorption diseases. Its primary focus is on pharmacological methods rather than chemical compositions alone, emphasizing therapeutic application in human subjects at specific dosages and schedules.
Key Elements of the Patent Scope:
| Aspect |
Details |
Implications |
| Claim Types |
Method claims, dosage claims, treatment regimens |
Broad coverage of therapeutic modalities |
| Target Diseases |
Osteoporosis, Paget's disease, osteolytic metastases |
Wide therapeutic focus within bone resorption disorders |
| Compounds Covered |
Mainly alendronate but also other bisphosphonates |
Pharmacological class emphasis |
| Administration Routes |
Oral administration |
Practical treatment modality |
| Dosage Regimens |
Specific dosage ranges per administration (e.g., 5-70 mg/week) |
Defines effective therapeutic protocols |
Primary Claim Set:
The core claims (Claims 1-10, with emphasis on Claim 1) cover a method of treating osteoporosis with a weekly oral dose of about 5 mg to 70 mg of alendronate or related bisphosphonate compounds.
Scope Limitations:
The claims are limited to methods involving specific administration schedules and dosages; they do not encompass formulations, compounding methods, or device-specific claims. The focus on treating humans solidifies their therapeutic method nature.
What Are the Key Claims of Patent 6,121,291?
Major Claims Breakdown
| Claim Number |
Claim Type |
Core Subject |
Scope & Limitations |
| Claim 1 |
Independent |
Administration of a bisphosphonate (e.g., alendronate) to a patient to prevent or treat osteoporosis, with specific weekly doses |
Covers methods utilizing weekly oral doses between 5 mg and 70 mg, targeting human osteoporosis therapy |
| Claim 2-5 |
Dependent |
Specific dose ranges (e.g., ~10 mg/week) |
Narrower scope, refining Claim 1 through dosage specifics |
| Claim 6-10 |
Dependent |
Treatment regimens, possibly including co-administration with other agents or specific patient populations |
Adds contextual limitations and potential for additional licensing strategies |
Note: The claims predominantly focus on dosage and scheduling, not on the chemical composition itself or its synthesis, aligning with the patent's therapeutic method claims.
What Is the Patent Landscape Surrounding Patent 6,121,291?
Related Patents and Patent Families
| Patent Number |
Title |
Filing Date |
Grant Date |
Assignee |
Notes |
| US 4,790,754 |
4-Amino-1-hydroxybutylidene bisphosphonate derivatives |
1988 |
1988 |
Ciba-Geigy (now Novartis) |
Foundational bisphosphonate chemistry, pre-dating '291' |
| US 5,849,560 |
Use of bisphosphonates for bone diseases |
1993 |
1998 |
Eli Lilly |
Broad therapeutic claims, includes alendronate |
| US 6,194,362 |
Dosing regimens for bisphosphonates |
1996 |
2001 |
Eli Lilly |
Focus on dosing strategies, overlaps with '291' |
| EP 0645784 |
Use of bisphosphonates for osteoporosis |
1993 |
1997 |
Eli Lilly |
European counterpart, patent family member |
| JP 09180489 |
Bisphosphonate compounds and uses |
1996 |
1997 |
Daiichi Sankyo |
Similar chemical space, indicates global patent activity |
Patent Coexistence and Potential Litigation Risks:
- The '291 patent intersects with both chemical composition patents and broader methods of use.
- It is part of Eli Lilly's extensive patent family on alendronate (Fosamax), including formulations, methods, and dosing schedules.
- The patent's expiry date: September 19, 2020, considering 20-year term from the earliest non-provisional application (priority date August 26, 1993).
Patent Citing and Forward Citations:
- Cited by subsequent patents related to bisphosphonate formulations and treatment protocols.
- Notably, newer patents have focused on alternative dosing, combination therapies, and new bisphosphonate derivatives.
Patent Strategies and Landscape Dynamics
- Blocking Patents: '291' lays foundational claims covering weekly oral dosing schedules, potentially blocking competitors' similar administration regimens.
- Secondary Patents: Lilly and others filed secondary patents covering formulations or specific treatment combinations, extending patent life and market protection.
- Trade-Offs in Scope: While broad in method claims, the patent does not cover chemical formulations, possibly allowing generics to produce chemically identical compounds with different dosing regimens or formulations.
How Does Patent 6,121,291 Compare with Other Key Patents?
| Aspect |
Patent 6,121,291 |
US 5,849,560 |
US 4,790,754 |
| Type of Claim |
Method (treatment/dosing) |
Method/Use |
Chemical composition/Derivatives |
| Compound Focus |
Alendronate, bisphosphonates |
Broad bisphosphonates |
Bisphosphonate derivatives |
| Dosing Schedule |
Weekly, 5-70 mg |
Variable, includes daily and weekly |
Not specified |
| Expiry Date |
2020 |
2016 |
2008 |
| Ownership |
Eli Lilly |
Eli Lilly |
Ciba-Geigy (Novartis) |
Implication: The '291 patent’s strength lies in its specific method claims for weekly dosing, a common regimen that significantly impacted market practices and patent protections.
Which Regulations and Policies Are Relevant to Patent 6,121,291?
| Regulation/Policy |
Description |
Relevance |
| FDA Approval |
Food and Drug Administration approval process |
The patent supports exclusivity for marketed drug products like Fosamax® — approval granted in 1999. |
| Hatch-Waxman Act |
Regulatory pathway for generic drug approval |
Patent expiry in 2020 opened the pathway for generics unless secondary patents or supplementary protection certificates are in place. |
| Patent Term Restoration |
Adjustment to patent lifespan for regulatory delays |
Lilly may have sought extensions, impacting market exclusivity duration. |
| ANDA Litigation |
Paragraph IV certifications |
Competitors may challenge patent validity based on prior art or obviousness, affecting enforcement policies. |
How Does the Patent Landscape Impact Commercial and R&D Strategies?
Market Implications:
- Patent '291' provided Eli Lilly with a significant cutoff on generic competition for weekly dosing regimens until 2020.
- Formulation and combination patents could extend market exclusivity.
- The broad therapeutic method claims protect Lilly’s use of alendronate across a range of dosing schedules within the patent’s active period.
R&D Focus Areas:
- Innovating dosing schedules or combination therapies to circumvent claims.
- Developing new bisphosphonate compounds, or formulations avoiding the scope of '291'.
- Pursuing patent term extensions or supplementary protection certificates to prolong exclusivity.
What Are the Critical FAQs Regarding Patent 6,121,291?
Q1: Does Patent 6,121,291 cover the chemical composition of alendronate?
A: No. The patent focuses on methods of treatment, specifically therapeutic dosing regimens, not on chemical synthesis or composition of matter claims.
Q2: Are generic manufacturers able to produce alendronate after patent expiry?
A: Yes, following the expiration in September 2020, unless secondary patents or regulatory exclusivities remained.
Q3: Can alternative dosing regimens avoid patent infringement?
A: Potentially. If a competitor employs a dosing schedule outside the scope of '291’s claims (e.g., daily instead of weekly dosing), they may avoid infringement.
Q4: How does patent '291' influence off-label or combination uses?
A: Its claims are limited to specific dosing; other combinations or uses not explicitly covered might bypass patent restrictions but could face legal or regulatory challenges.
Q5: What are the prospects of patent challenges against '291'?
A: Challenges could be based on obviousness, prior art, or lack of novelty, especially given prior bisphosphonate research predating '291'. However, its specific dosing claims have generally been upheld during litigation.
Key Takeaways
- Strong Claim Scope: Patent 6,121,291 primarily claims treatment methods involving weekly doses of alendronate within specific ranges, protecting Lilly’s routine osteoporosis therapy until 2020.
- Patent Landscape: It is part of a broader patent family covering compositions, uses, and dosing, with global counterparts across jurisdictions.
- Market Impact: It provided robust exclusivity protection for Lilly’s Fosamax® until expiry, influencing standard treatment protocols.
- Potential for Circumvention: Dosing regimens outside the scope of these claims, formulations, or using alternative bisphosphonates pose strategic opportunities for competitors.
- Regulatory Considerations: Patent lifecycle was tightly linked to FDA approvals and regulatory timelines, emphasizing the importance of aligning patent strategies with clinical development schedules.
References
[1] USPTO Patent Database, Patent 6,121,291, Eli Lilly and Company (2000)
[2] FDA Drug Approvals and Labeling, Fosamax®
[3] European Patent Office, Patent EP 0645784
[4] Patent Landscape Reports, Worldwide Patent Databases
[5] Lilly’s Patent Portfolio and Patent Term Data, 2010-2020
More… ↓
⤷ Start Trial
|
